human multiple tissue cdna panel (TaKaRa)
TaKaRa is a verified supplier 
TaKaRa manufactures this product 
95
Structured Review
TaKaRa
human multiple tissue cdna panel
Human Multiple Tissue Cdna Panel, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 605 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tissue+cdna+panels/Human+MTC+Panel+I/pm40037881-24-4-17
Average 95 stars, based on 605 article reviews
Human Multiple Tissue Cdna Panel, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 605 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tissue+cdna+panels/Human+MTC+Panel+I/pm40037881-24-4-17
Average 95 stars, based on 605 article reviews
human multiple tissue cdna panel - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Expressing:Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: MASP isoforms as inhibitors of complement activation Article Snippet: .. Tissue expression of the FAP fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Method of treating diabetes by a CTRP12 polypeptide Article Snippet: .. CTRP12 tissue expression analysis was performed using mouse and Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Polymerase Chain Reaction:Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: MASP isoforms as inhibitors of complement activation Article Snippet: .. Tissue expression of the FAP fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available Article Title: Chimeric inhibitor molecules of complement activation Article Snippet: .. Tissue Expression of the FAP Fragment Methods: Commercially available |
![ROPN1/B is absent in healthy tissues and highly and homogenously present in primary and metastatic TNBC independent of pretreatment. A, Flowchart of the discovery of ROPN1/B as a target for T-cell treatment of TNBC and validation of its tumor-restricted expression using healthy tissues, as well as primary and metastatic TNBC tissues. Intracellular targets (CGAs: n = 276) were screened for absent expression in healthy tissues ( n = 1,479 tissues) and expression in TNBC ( n = 191 tissues). ROPN1/B mRNA and protein expression was further validated in multiple sets of healthy tissues (two additional cohorts) and four different cohorts of patient tumor tissues (see “Methods” for details). B, Dot plot shows gene expressions as fold changes relative to GAPDH (2 −dCt ) according <t>to</t> <t>RT-qPCR</t> using a <t>cDNA</t> library of 48 healthy tissue samples. NY-ESO1 was used as a reference. Green, ROPN1 ; purple, ROPN1B ; gray, NY-ESO1 ( CTAG1B ), n = 2 to 3 per target antigen. C, Representative immune stainings of ROPN1/B using an array of 14 healthy tissues (2–6 donors per tissue, total n = 66). D, Violin plots show the distribution of gene expression of NY-ESO1 ( CTAG1B , gray) and ROPN1 (green) in TNBC cohort 1 ( n = 66, geTMM normalized) and cohort 2 ( n = 183, fRMA-normalized; see “Methods” for details on cohorts). Data were analyzed using the Wilcoxon signed-rank test: cohort 1: P < 2.2E16; cohort 2: P < 2.2E16. E, Representative immune stainings of TNBC categorized according to staining intensity with different intensities for NY-ESO1 (top) and ROPN1/B (bottom). Stacked bar graphs (middle) show the fraction of TNBC tumors with weak, moderate, and strong immune staining of NY-ESO1 or ROPN1/B [tissue microarrays (TMA), n = 311]. Stacked bar graphs (right) show fractions of TNBC tumors with either 1% to 9%, 10% to 25%, 26% to 50%, or 51% to 100% of tumors cells positive for NY-ESO1 or ROPN1/B protein; the latter category of 51% to 100% ROPN1-stained cells is further subdivided into the fractions: 51% to 75%, 76% to 90%, and 91% to 100% (in zoomed-in stacked bar). F, Violin plot shows the distribution of gene expressions of ROPN1/B in primary and metastatic TNBC from TNBC cohort 1 ( n = 66, geTMM normalized) and cohort 3 ( n = 22) following batch correction. Data were analyzed using the Wilcoxon signed-rank test: P = 0.61. G, Stacked bar graphs (left) show the fraction of primary and metastatic TNBC with weak, moderate, and strong immune staining of ROPN1/B (whole tissue sections, n = 15 paired samples). Stacked bar graphs (right) show the fraction of primary and metastatic TNBC with either 1% to 9%, 10% to 25%, 26% to 50%, or 51% to 100% of tumor cells positive for ROPN1/B. H, Violin plots show the distribution of gene expression of ROPN1/B in pre- and post-induction treatment biopsies of metastatic TNBC retrieved from cohort 4 ( n = 53 of which n = 44 are paired samples, geTMM normalized). Data of paired pre/postsamples was analyzed using the Wilcoxon signed-rank test: cisplatin: n = 8, P = 0.4; cyclophosphamide: n = 10, P = 1; doxorubicin: n = 9, P = 0.4; irradiation: n = 7, P = 0.7; no induction: n = 10, P = 0.73. ACT: L. intestine, Large intestine; S. intestine, small intestine.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9630/pmc11609630/pmc11609630__cd-24-0168fig1.jpg)
